Seacross is pleased to announce the launch of Irinotecan hydrochloride 20 mg/ml solution in July, 2015.
Irinotecan hydrochloride 20 mg/ml solution is fully licensed with UK Medicines and Healthcare products Regulatory Agency (MHRA) with license number PL 41013/0001. Seacross has been awarded an NHS tender and is successfully supplying product in strengths of 40 mg/2ml, 100 mg/5ml, 300 mg/15ml, 500 mg/25ml in the UK.
